Xencor Inc (XNCR) Major Shareholder John S. Stafford III Acquires 1,100 Shares
Xencor Inc (NASDAQ:XNCR) major shareholder John S. Stafford III bought 1,100 shares of the firm’s stock in a transaction dated Monday, March 18th. The shares were acquired at an average cost of $29.90 per share, with a total value of $32,890.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
XNCR stock traded down $0.15 during trading on Tuesday, reaching $30.27. The stock had a trading volume of 85,380 shares, compared to its average volume of 218,693. Xencor Inc has a one year low of $27.57 and a one year high of $48.38. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of -23.11 and a beta of 1.40.
Several research firms have recently commented on XNCR. Cantor Fitzgerald reissued an “overweight” rating on shares of Xencor in a research report on Friday, November 23rd. BidaskClub raised shares of Xencor from a “hold” rating to a “buy” rating in a research report on Tuesday, January 1st. Nomura downgraded shares of Xencor from a “neutral” rating to a “reduce” rating and reduced their price objective for the stock from $28.00 to $21.00 in a research report on Friday, February 22nd. Zacks Investment Research raised shares of Xencor from a “hold” rating to a “buy” rating and set a $38.00 price objective for the company in a research report on Thursday, December 20th. Finally, Raymond James assumed coverage on shares of Xencor in a research report on Thursday, March 14th. They issued an “outperform” rating and a $27.85 price objective for the company. Two equities research analysts have rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. Xencor currently has an average rating of “Buy” and a consensus target price of $40.43.
COPYRIGHT VIOLATION NOTICE: This news story was published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.watchlistnews.com/xencor-inc-xncr-major-shareholder-john-s-stafford-iii-acquires-1100-shares/2902577.html.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Recommended Story: What Does a Sell-Side Analyst Rating Mean?
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.